Taiwan Associated Genetic and Nongenetic Small Vessel Disease

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 24, 2022

Keywords

ClinConnect Summary

The Taiwan Associated Genetic and Nongenetic Small Vessel Disease (TAG-SVD) trial is studying a type of brain condition called cerebral small vessel disease (CSVD). This condition can lead to problems like strokes, cognitive decline, and movement difficulties. The trial aims to understand how genetic factors contribute to CSVD by looking at specific genes in patients. Participants will undergo a special genetic test and will be monitored for at least two years to see how their condition progresses.

To be eligible for this trial, participants should be experiencing symptoms such as strokes, memory issues, balance problems, or headaches, and they should have MRI scans showing signs of CSVD. It's important to note that individuals with CSVD caused by other medical conditions won't be able to participate. If you join the study, you will receive genetic testing and regular follow-ups to track your health over time. This research could help improve understanding and treatment of CSVD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have at least one of the following symptoms/signs or history
• • stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke)
• • cognitive impairment or dementia
• • gait disturbance
• • parkinsonism (especially vascular parkinsonism features)
• • headache (especially migraine)
• • positive family history of hereditary CSVD
• • MRI evidence of CSVD (MRI may be done for other reasons), including mild to moderate white matter hyper intensity, any lacune, or any cerebral microbleed
• Exclusion Criteria:
• • MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions
• • patients or family members not willing to sign informed consent